Imiquimod
| Code | Size | Price |
|---|
| AG-CR1-3569-M100 | 100 mg | £55.00 |
Quantity:
| AG-CR1-3569-M250 | 250 mg | £95.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
+4deg;C
Documents
Further Information
Alternate Names/Synonyms:
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; S26308; R-837
Appearance:
White to off-white powder.
CAS:
99011-02-6
Class:
6.1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS06
Handling Advice:
After reconstitution, prepare aliquots and store at -20°C.
Hazards:
H300, H315, H319, H335
InChi:
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChiKey:
DOUYETYNHWVLEO-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 99011-02-6. Formula: C14H16N4. MW: 240.3. Immune response modulator. Anti-inflammatory. TLR7 agonist. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB. Caspase-3 activator that directly induces procaspase-3 cleavage. Anti-cancer compound. Apoptosis inducer. Antiproliferative, independent of immune system activation or function. Antiviral and anti-angiogenic. Approved treatment for external genital warts caused by human papillomavirus infection.
MDL:
MFCD00866946
Molecular Formula:
C14H16N4
Molecular Weight:
240.3
Package Type:
Vial
PG:
III
Precautions:
P301, P310, P312, P330
Product Description:
Immune response modulator [1, 2]. Anti-inflammatory [3, 5]. TLR7 agonist [3, 5]. Stimulates proinflammatory cytokine production interferon-alpha (IFN-alpha), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) and activates NF-kappaB [3, 5]. Caspase-3 activator that directly induces procaspase-3 cleavage [4]. Anti-cancer compound [4, 9]. Apoptosis inducer [4, 9]. Antiproliferative, independent of immune system activation or function. Antiviral [10] and anti-angiogenic [6, 7, 8]. Approved treatment for external genital warts caused by human papillomavirus infection [10].
Purity:
>98%
Signal word:
Danger
SMILES:
CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
Solubility Chemicals:
Soluble in DMSO or dimethylformamide. Insoluble in ethanol. Slightly soluble in water.
Transportation:
Excepted Quantity
UN Nummer:
UN 2811
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C. Stock solutions are stable for at least 3 months when stored at -20°C.
References
Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999) | A review of the applications of imiquimod: a novel immune response modifier: T.A. Syed, et al.; Exp. Opin. Pharmacother. 2, 877 (2001) | Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002) | Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod: M. Schon, et al.; J. Natl. Cancer Inst. 95, 1138 (2003) | Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003) | In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004) | Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005) | Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005) | The antitumoral mode of action of imiquimod and other imidazoquinolines: M. Schon & M.P. Schon; Curr. Med. Chem. 14, 681 (2007) | The pharmacology of endosomal TLR agonists in viral disease: D.R. Averett, et al.; Biochem. Soc. Trans. 35, 1468 (2007) | TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother. ahead of print (2018)